951-P: MiniMed 780G System Use with Fast-Acting Insulin Aspart by Adults with T1D

Résumé fourni par la source

Introduction and Objective: Automated insulin delivery with fast-acting insulin aspart (Fiasp™) is demonstrated safe and non-inferior in A1C reduction, compared with rapid-acting insulin (RAI).1 The present study reports on glycemic outcomes and safety of MiniMed™ 780G system (MM780G) use with Fiasp by adults. Methods: Ten centers enrolled adults with T1D (N=116 intention-to-treat, 18-80yrs) who used the MM780G with the Medtronic extended infusion set in a run-in (~2wks) of open loop or automated basal with aspart or lispro (glucose target [GT] of 120mg/dL). This was followed by a 3-month study period of AHCL at a 100, 110 or 120mg/dL GT with Fiasp. Glycemic outcomes and insulin during the last ~6wks of the study (system settings at investigator discretion) were compared to those during run-in. Outcomes with recommended optimal settings (ROS, 100mg/dL GT with 2hrs active insulin time) were, also, assessed and safety was summarized. Results: Study-period AHCL+Fiasp significantly increased time in range (TIR) and significantly reduced A1C, mean sensor glucose (SG) and time spent below and above range, with no change in TDD (Table). ROS use was associated with an even higher TIR and lower A1C, mean SG and TAR. There was one severe hypoglycemia event (unrelated to device) and no DKA. Conclusion: These findings show that Fiasp is safe when used with MM780G AHCL and provides improved glycemic outcomes when compared to RAI with open-loop or HCL use. Disclosure H.K. Akturk: Consultant; Dexcom, Inc., Medtronic, Tandem Diabetes Care, Inc, Novo Nordisk. Research Support; Dexcom, Inc., Medtronic, Tandem Diabetes Care, Inc, Novo Nordisk. J.H. Reed: None. J. Thrasher: Advisory Panel; Medtronic. Board Member; Medtronic. Consultant; Medtronic. Research Support; Medtronic, AstraZeneca, Merck & Co., Inc, Novo Nordisk, Lilly Diabetes, Inversago Pharma. A. Abitbol: Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Research Support; Eli Lilly and Company. Advisory Panel; Abbott. Research Support; Abbott. Speaker's Bureau; Abbott. Advisory Panel; Dexcom, Inc. Research Support; Dexcom, Inc. Speaker's Bureau; Dexcom, Inc. Research Support; Biomea Fusion. Advisory Panel; Biomea Fusion. Research Support; Zucara Therapeutics, Moderna, Inc, Pfizer Inc, GlaxoSmithKline plc. Advisory Panel; GlaxoSmithKline plc. Speaker's Bureau; Novartis Pharmaceuticals Corporation. Advisory Panel; Novartis Pharmaceuticals Corporation. Research Support; Novartis Pharmaceuticals Corporation. Advisory Panel; Bayer Pharmaceuticals, Inc, Insulet Corporation. Research Support; Medtronic. M.L. Warren: Research Support; Medtronic, Insulet Corporation, Abbott. Speaker's Bureau; Lilly Diabetes. Research Support; Lilly USA LLC, Amgen Inc. Speaker's Bureau; Amgen Inc. Advisory Panel; Lilly USA LLC. Research Support; Diasome Pharmaceuticals, Bayer Pharmaceuticals, Inc, Ascendis Pharma A/S, Novo Nordisk. F.E. Broyles: None. D. Reyes: None. Z. Dai: Employee; Metronics. J. Shin: Employee; Medtronic. T.L. Cordero: Employee; Medtronic. J.J.F. McVean: Employee; Medtronic. A.S. Rhinehart: Employee; Medtronic. Stock/Shareholder; Medtronic. R.A. Vigersky: Employee; Medtronic.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.